Tag: GLP-1
-
Aspen Pharmacare Asset Disposals: Future Opportunities
Multinational pharmaceutical giant Aspen Pharmacare is prepared to further streamline its global operations. While the company has not officially hoisted a “for sale” sign, leadership has indicated it remains open to further Aspen Pharmacare asset disposals if the price is right. This strategic openness follows the landmark sale of its Asia-Pacific (APAC) division. The R26.5 billion transaction serves as a…
-
Aspen Pharmacare Debt-Free: Strategic Shift To GLP-1 Injectables
Aspen Pharmacare has officially closed the chapter on its leveraged era. For the first time since the company was founded in 1997, CEO Stephen Saad has confirmed the group is debt-free. This significant milestone follows the massive sale of its Asia-Pacific operations (excluding China) to BGH Capital. The deal, concluded at the end of last year, was valued at A$2.37…
-
Eli Lilly 2026 Guidance Signals Momentum In Obesity Care
Eli Lilly has forecast 2026 profit and revenue above Wall Street expectations, reinforcing how fast the obesity market is reshaping Big Pharma growth plans. The recent Eli Lilly 2026 Guidance reflects the company’s confidence in strong future performance. The company also beat estimates for fourth-quarter earnings, helped by strong demand for its injectable weight-loss and diabetes medicines. For Q4, Lilly…
-
Generic Semaglutide Set to Disrupt Global GLP‑1 Market
Aspen Pharmacare is gearing up to launch one of the world’s first generic semaglutide in Canada, capitalising on the recent loss of patent protection for Novo Nordisk’s blockbuster GLP‑1 weight‑loss injection. The move could be a pivotal moment for access and competition in an increasingly lucrative market. Canada’s early patent expiry of semaglutide has drawn global attention. Industry leaders see…
-
GLP-1 Weight Loss Drugs Reshape Obesity Care In South Africa
South Africa’s fight against obesity has entered a decisive phase, driven by a surge in the medicalisation of treatment through GLP-1 weight loss drugs. In early 2026, two major medications, Mounjaro (tirzepatide) and Wegovy (semaglutide), have received key regulatory approvals, marking a new chapter in primary healthcare. With nearly 4.5 million South African adults living with obesity, the shift comes…
-
GLP-1 Medicines Review: South Africa Moves to Expand Access
The National Essential Medicines List Committee (NEMLC) has officially prioritised a GLP-1 medicines review. This move signals a potential shift in how South Africa manages the dual crises of type 2 diabetes and obesity. According to senior health department officials, the review aims to determine whether these high-demand drugs should be added to the Essential Medicines List (EML). If approved,…
-
Illegal weight loss injections: The rising black market crisis
The quest for rapid weight loss in South Africa has birthed a dangerous shadow economy. For many, acquiring potent GLP-1 agonists no longer requires a clinical consultation. Instead, it involves a few WhatsApp messages and a payment to a stranger. This burgeoning trade in illegal weight loss injections highlights a desperate intersection of public health needs and economic barriers. As…
-
Surge in Illicit Medicines Threatens Public Health
South Africa is at a critical crossroads in its fight against a rising tide of illicit, substandard, and falsified medicines. These pose a severe threat to public health. The influx is particularly alarming in relation to GLP-1 agonists, the popular class of medicines developed to treat type 2 diabetes and obesity. In response to this escalating crisis, the South African…
-
Cheaper Weight-Loss Drugs for Global Health Needs
\n\nThe decision directly affects the popular GLP-1 agonist drugs, including the active ingredients in brands like Ozempic, Wegovy, and Mounjaro. \n\n\n\nThe WHO’s recommendation aims to pressure pharmaceutical giants to lower prices and encourage the production of affordable generic versions. This is particularly important for people in developing countries, where they are needed most.\n\n\n\nThis move underscores the severity of the global…
-
GLP-1 Drugs Lower Cancer Rates in Weight Loss Study
New findings suggest that popular GLP-1 drugs, widely prescribed for weight loss and type 2 diabetes, may significantly influence a patient’s risk of developing certain cancers. This is mainly for the better. A comprehensive review of medical records has uncovered a compelling link. It found that the use of GLP-1 agonists – such as Ozempic, Wegovy, Mounjaro, and Zepbound –…